Evidence mapPaperPMID 32040531Full record

Observational studyPloS one2020

Risk assessment for hospital admission in patients with COPD; a multi-centre UK prospective observational study.

Jilles M Fermont, Charlotte E Bolton, Marie Fisk, Divya Mohan, William Macnee, John R Cockcroft, Carmel McEniery, Jonathan Fuld, Joseph Cheriyan, Ruth Tal-Singer and 4 more

Open access · goldAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Observational
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 2 countries.

Jilles M FermontDivision of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, England, United Kingdom.ORCID 0000-0001-5042-5785
Charlotte E BoltonDivision of Respiratory Medicine and NIHR Nottingham BRC Respiratory Theme, School of Medicine, University of Nottingham, Nottingham, England, United Kingdom.ORCID 0000-0002-9578-2249
Marie FiskDivision of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, England, United Kingdom.ORCID 0000-0002-1292-7642
Divya MohanMedical Innovation, Value Evidence and Outcomes GSK, Collegeville, PA, United States.
William MacneeCentre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, Scotland, United Kingdom.
John R CockcroftDepartment of Cardiology, Columbia University Medical Centre, New York, New York, United States.
Carmel McEnieryDivision of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, England, United Kingdom.
Jonathan FuldDepartment of Respiratory Medicine, Cambridge University Hospitals NHS Foundation Trust, Cambridge, England, United Kingdom.
Joseph CheriyanDivision of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, England, United Kingdom.ORCID 0000-0001-6921-1592
Ruth Tal-SingerMedical Innovation, Value Evidence and Outcomes GSK, Collegeville, PA, United States.ORCID 0000-0002-5275-8062
Ian B WilkinsonDivision of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, England, United Kingdom.
Angela M WoodBritish Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, England, United Kingdom.
Michael I PolkeyDepartment of Respiratory Medicine, Royal Brompton Hospital, London, England, United Kingdom.ORCID 0000-0003-1243-8571
Hana MüllerovaEpidemiology, Value Evidence and Outcomes GSK, Uxbridge, England, United Kingdom.ORCID 0000-0002-0949-0101
University of Cambridge · GBGlaxoSmithKline (United States) · USCambridge University Hospitals NHS Foundation Trust · GBColumbia University Irving Medical Center · USHealth Economics and Outcomes Research (United Kingdom) · GBQueen's Medical Centre · GBRoyal Brompton Hospital · GBUniversity of Nottingham · GB

Funding

British Heart Foundation RG/13/13/30194British Heart Foundation RG/18/13/33946Chief Scientist OfficeDepartment of HealthMedical Research Council G0701619Medical Research Council MR/K014811/1Medical Research Council MR/L003120/1Wellcome Trust
6 · The paper itself

Abstract

In chronic obstructive pulmonary disease (COPD), acute exacerbation of COPD requiring hospital admission is associated with mortality and healthcare costs. The ERICA study assessed multiple clinical measures in people with COPD, including the short physical performance battery (SPPB), a simple test of physical function with 3 components (gait speed, balance and sit-to-stand). We tested the hypothesis that SPPB score would relate to risk of hospital admissions and length of hospital stay. Data were analysed from 714 of the total 729 participants (434 men and 280 women) with COPD. Data from this prospective observational longitudinal study were obtained from 4 secondary and 1 tertiary centres from England, Scotland, and Wales. The main outcome measures were to estimate the risk of hospitalisation with acute exacerbation of COPD (AECOPD and length of hospital stay derived from hospital episode statistics (HES). In total, 291 of 714 individuals experienced 762 hospitalised AECOPD during five-year follow up. Poorer performance of SPPB was associated with both higher rate (IRR 1.08 per 1 point decrease, 95% CI 1.01 to 1.14) and increased length of stay (IRR 1.18 per 1 point decrease, 95% CI 1.10 to 1.27) for hospitalised AECOPD. For the individual sit-to-stand component of the SPPB, the association was even stronger (IRR 1.14, 95% CI 1.02 to 1.26 for rate and IRR 1.32, 95% CI 1.16 to 1.49 for length of stay for hospitalised AECOPD). The SPPB, and in particular the sit-to-stand component can both evaluate the risk of H-AECOPD and length of hospital stay in COPD. The SPPB can aid in clinical decision making and when prioritising healthcare resources.

Indexed as

AgedFemaleHospitalizationHumansLength of StayLongitudinal StudiesMaleMiddle AgedOutcome Assessment, Health CarePatient AdmissionPhysical Functional PerformanceProspective StudiesPulmonary Disease, Chronic ObstructiveRisk AssessmentUnited Kingdom

Identifiers

PMID32040531
PMCPMC7010290
OpenAlexW3005303779

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.